Distinct anti-NP, anti-RBD and anti-Spike antibody profiles discriminate death from survival in COVID-19

IntroductionInfection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces rapid production of IgM, IgA, and IgG antibodies directed to multiple viral antigens that may have impact diverse clinical outcomes.MethodsWe evaluated IgM, IgA, and IgG antibodies directed to the nucleocap...

Full description

Saved in:

Bibliographic Details
Published in:	Frontiers in immunology Vol. 14; p. 1206979
Main Authors:	Servian, Carolina do Prado, Spadafora-Ferreira, Mônica, Anjos, Déborah Carolina Carvalho dos, Guilarde, Adriana Oliveira, Gomes-Junior, Antonio Roberto, Borges, Moara Alves Santa Bárbara, Masson, Letícia Carrijo, Silva, João Marcos Maia, de Lima, Matheus Henrique Assis, Moraes, Brenda Grazielli Nogueira, Souza, Sueli Meira, Xavier, Luiz Eterno, de Oliveira, Denise Cristina André, Batalha-Carvalho, João Victor, Moro, Ana Maria, Bocca, Anamélia Lorenzetti, Pfrimer, Irmtraut Araci Hoffmann, Costa, Nádia Lago, Feres, Valéria Christina de Rezende, Fiaccadori, Fabiola Souza, Souza, Menira, Gardinassi, Luiz Gustavo, Durigon, Edison Luiz, Romão, Pedro Roosevelt Torres, Jorge, Soraia Attie Calil, Coelho, Verônica, Botosso, Viviane Fongaro, Fonseca, Simone Gonçalves
Format:	Journal Article
Language:	English
Published:	Frontiers Media S.A 09-10-2023
Subjects:	antibodies COVID-19 Immunology nucleocapsid protein (N) receptor binding domain (RBD) SARS-CoV-2 spike protein (S)
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	IntroductionInfection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces rapid production of IgM, IgA, and IgG antibodies directed to multiple viral antigens that may have impact diverse clinical outcomes.MethodsWe evaluated IgM, IgA, and IgG antibodies directed to the nucleocapsid (NP), IgA and IgG to the Spike protein and to the receptor-binding domain (RBD), and the presence of neutralizing antibodies (nAb), in a cohort of unvaccinated SARS-CoV-2 infected individuals, in the first 30 days of post-symptom onset (PSO) (T1).ResultsThis study included 193 coronavirus disease 2019 (COVID-19) participants classified as mild, moderate, severe, critical, and fatal and 27 uninfected controls. In T1, we identified differential antibody profiles associated with distinct clinical presentation. The mild group presented lower levels of anti-NP IgG, and IgA (vs moderate and severe), anti-NP IgM (vs severe, critical and fatal), anti-Spike IgA (vs severe and fatal), and anti-RBD IgG (vs severe). The moderate group presented higher levels of anti-RBD IgA, comparing with severe group. The severe group presented higher levels of anti-NP IgA (vs mild and fatal) and anti-RBD IgG (vs mild and moderate). The fatal group presented higher levels of anti-NP IgM and anti-Spike IgA (vs mild), but lower levels of anti-NP IgA (vs severe). The levels of nAb was lower just in mild group compared to severe, critical, and fatal groups, moreover, no difference was observed among the more severe groups. In addition, we studied 82 convalescent individuals, between 31 days to 6 months (T2) or more than 6 months (T3), PSO, those: 12 mild, 26 moderate, and 46 severe plus critical. The longitudinal analyzes, for the severe plus critical group showed lower levels of anti-NP IgG, IgA and IgM, anti-Spike IgA in relation T3. The follow-up in the fatal group, reveals that the levels of anti-spike IgG increased, while anti-NP IgM levels was decreased along the time in severe/critical and fatal as well as anti-NP IgG and IgA in several/critical groups.DiscussionIn summary, the anti-NP IgA and IgG lower levels and the higher levels of anti-RBD and anti-Spike IgA in fatal compared to survival group of individuals admitted to the intensive care unit (ICU). Collectively, our data discriminate death from survival, suggesting that anti-RBD IgA and anti-Spike IgA may play some deleterious effect, in contrast with the potentially protective effect of anti-NP IgA and IgG in the survival group.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Reviewed by: Diego Cantoni, MRC-University of Glasgow Centre For Virus Research (MRC), United Kingdom; Soumya SenGupta, Institute of Life Sciences (ILS), India Edited by: Javier Castillo-Olivares, Coalition for Epidemic Preparedness Innovations (CEPI), Norway
ISSN:	1664-3224 1664-3224
DOI:	10.3389/fimmu.2023.1206979